Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients

Transplantation

Volumn 79, Issue 11, 2005, Pages 1596-1606

  Güngör, Tayfun ^a   Halter, Jörg ^b   Klink, Anne ^b   Junge, Sonja ^a   Stumpe, Katrin D M ^b   Seger, Reinhard ^a   Schanz, Urs ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adult; Bone marrow transplantation; Chronic granulomatous disease; Low toxicity conditioning; Marrow and stem cell transplantation

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN A; DIPHTHERIA TETANUS TOXOID; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; GENTAMICIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; ITRACONAZOLE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; SUPEROXIDE; THYMOCYTE ANTIBODY; VANCOMYCIN; VORICONAZOLE;

ADULT; AGE DISTRIBUTION; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CASE REPORT; COLITIS; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; EPILEPSY; ERYTHROCYTE APLASIA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRANULOMATOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LIVER ABSCESS; LIVING DONOR; LUNG DISEASE; LYMPHOCYTE FUNCTION; MALE; MORTALITY; NEUTROPHIL; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; STEROID DEPENDENT GRANULOMATOUS COLITIS; T LYMPHOCYTE; THROMBOCYTE; TOXICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; B-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; MALE; NEUTROPHILS; RESPIRATORY FUNCTION TESTS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CHIMERA; TREATMENT OUTCOME;

EID: 20544436474     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000163466.73485.5E     Document Type: Article

References (40)

1. Margolis DM, Melnick DA, Alling DW, et al. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162: 723-726.
2. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 348: 2416-2422.
3. The International Chronic Granulomatous Disease Cooperative Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509-516.
4. Winkelstein JA, Marino MC, Johnston RB, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 2000; 79: 155-169.
5. Hasui M. Chronic granulomatous disease in Japan: Incidence and natural history. The Study Group of Phagocyte Disorders of Japan. Pediatr Int 1999; 41: 589-593.
6. Forster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998; 102: 2146-2155.
7. Seger RA, Gungor T, Belohradsky BH, et al. A. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002; 100: 4344-4450.
8. Horwitz ME, Barrett J, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881-888.
9. Giardini C, Lucarelli G. Bone marrow transplantation for Beta-thalassemia. Hematol Oncol Clin North Am 1999; 13: 1059-64.
10. Güngör T, Engel-Bicik I, Eich G, et al. Diagnostic and therapeutic impact of whole body positron emission tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose (FDG) in children with chronic granulomatous disease. Arch Dis Child 2001; 85: 341-345.
11. Bisset LR, Lung TL, Kaelin M, et al. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004; 72: 203-212.
12. Zhang L, Lewin SR, Markowitz M, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999; 190: 725-732.
13. Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 2002; 100: 2235-2242.
14. Storek J, Joseph A, Dawson MA, et al. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation 2002; 73: 1154-1158.
15. Ozsahin H, von Planta M, Müller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998; 92: 2719-2724.
16. Di Bartolomeo P, Di Girolamo G, Angrilli F, et al. Reconstitution of normal neutrophil function in chronic granulomatous disease by bone marrow transplantation. Bone Marrow Transplant 1989; 4: 695-700.
17. Nagler A, Ackerstein A, Kapelushnik J, et al. Donor lymphocyte infusion post-nonmyeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 1999; 24: 339-342.
18. Calvino MC, Madonado MS, Otheo E, et al. Bone marrow transplantation in chronic granulomatous disease. Eur J Pediat 1996; 155: 877-879.
19. Watanabe C, Yajima S, Taguchi T, et al. Successful unrelated bone marrow transplantation for a patient with chronic granulomatous disease and associated resistant pneumonitis and Aspergillus osteomyelitis. Bone Marrow Transplant 2001; 28: 83-87.
20. Hobbs JR, Monteil M, McCluskey DR, et al. Chronic granulomatous disease 100% corrected by displacement bone marrow transplantation from a volunteer unrelated donor. Eur J Pediatr 1992; 151: 806-810.
21. Yang S, Panoskaltsis-Mortari A, Shukla M, et al. Exuberant inflammation in nicotinamide adenine dinucleotide phosphate-oxidase-deficient mice after allogeneic marrow transplantation. J Immunol 2002; 168: 5840-5847.
22. Morgenstern DE, Gifford MAC, Lin Li L, et al. Absence of respiratory burst in X-linked chronic granulomatous disease and inflammatory response to Aspergillus fumigatus. J Exp Med 1997; 185: 207-218.
23. Schelenz S, Smith DA, Bancroft GJ. Cytokine and chemokine responses following pulmonary challenge with Aspergillus fumigatus: obligatory role of TNF-α and GM-CSF in neutrophil recruitment. Med Mycol 1999; 37: 183-194.
24. Van Deventer SJ. Tumor necrosis factor and Crohn's disease. Gut 1997; 40: 443-448.
25. Hill GR, Teshima T, Rebel VI, et al. The p55 TNF-α receptor plays a critical role in T cell alloreactivity. J Immunol 2000; 164: 656-663.
26. Hildebrandt GC, Olkiewicz KM, Corrion LA, et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 104: 586-593.
27. Hildebrandt GC, Duffner UA, Olkiewicz KM, et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 103: 2417-2426.
28. Panoskaltsis-Mortari A, Hermanson JR, Taras E, et al. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood 2003; 101: 3714-3721.
29. Cooke KR, Yanik G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant 2004; 34: 753-756.
30. Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 1994; 83: 288-298.
31. Roilides E, Dimitriadou-Georgiadou A, Sein T, et al. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998; 66: 5999-6003.
32. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 8: 2122-2127.
33. Slavin S, Nagler A, Naparstek, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
34. Akioka S, Itoh H, Ueda I, et al. Donor lymphocyte infusion at unstable mixed chimerism in an allogeneic BMT recipient for chronic granulomatous disease. Bone Marrow Transplant 1998; 22: 609-611.
35. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
36. Tanimoto TE, Yamaguchi T, Tanaka Y, et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004; 125: 480-493.
37. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
38. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
39. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
40. Yamaguchi M, Sakai K, Murata R, et al. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30: 539-541.